The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, BPC 157 Before and After: 1 Amazing Transformation FDA Peptide Update: Category 2 Removals Explained The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype